Business Context and Reporting Period
Company: Kura Oncology, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 13, 2025
Event: FDA full approval of KOMZIFTI (ziftomenib) for adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible NPM1 mutation and no satisfactory alternative treatment options.
Key Financial Metrics and Commercial Terms
Revenue and Profit: The filing does not provide specific revenue, profit, or cash flow figures for the reporting period.
Pricing: Wholesale acquisition cost set at $48,500 for a one-month supply of KOMZIFTI.
Debt and Liquidity: The filing does not provide data on debt levels or liquidity positions.
Material Changes and Clinical Data
The primary material change is the regulatory approval of the Company's lead asset, KOMZIFTI, marking it as the first and only once-daily, oral menin inhibitor approved for R/R NPM1-mutated AML. Key clinical data from the pivotal KOMET-001 trial (112 patients) include:
- Response Rate: 21.4% complete remission (CR) plus CR with partial hematologic recovery (CRh).
- Duration: Median duration of CR+CRh was 5.0 months.
- Time to Response: Median time to first response was 2.7 months; 88% of responders achieved CR/CRh within six months.
- Market Context: NPM1 mutations occur in approximately 30% of AML cases. Historically, 20% of patients do not respond to front-line therapy, and 70% of responders relapse within three years.
Guidance, Outlook, Risks, and Contingencies
Commercial Strategy: Under a global strategic collaboration with Kyowa Kirin Co., Ltd. (entered November 2024):
- United States: Kura Oncology leads development, regulatory, and commercial strategy and is responsible for manufacturing. Commercialization activities are performed jointly.
- Outside United States: Kyowa Kirin leads development, regulatory, and commercial strategy and is responsible for commercialization.
Risks and Safety:
- Boxed Warning: Differentiation syndrome is a mechanism-based risk.
- Adverse Reactions: Common reactions (≥20%) include increased aspartate/alanine aminotransferase, infection, electrolyte imbalances, hemorrhage, diarrhea, nausea, fatigue, and differentiation syndrome.
- QTc Prolongation: ≤ Grade 3 in 12% of patients; no Grade 4 or 5 reported. Occurred in 10% of patients aged 65 or older.
- Forward-Looking Risks: Includes potential unintended side effects, market competition, commercialization acceptance, and collaboration success.
Investor Verification Checklist
- Verify the specific terms of the commercialization revenue split and milestone payments in the Kyowa Kirin collaboration agreement.
- Confirm the timeline for product launch and initial sales projections in the U.S. market.
- Review the Company's most recent Form 10-Q (filed November 4, 2025) for current cash runway and burn rate to assess funding needs post-approval.
- Monitor post-market safety data regarding differentiation syndrome and QTc prolongation.
- Assess the competitive landscape for other menin inhibitors or AML therapies that may impact market share.